Aerospace and defense company BWX (NYSE:BWXT) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 18.7% year on year to $885.8 million. Its non-GAAP profit of $1.08 per share was 22.2% above analysts’ consensus estimates.
Aerospace and defense company Kratos (NASDAQ:KTOS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 21.9% year on year to $345.1 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $340 million was less impressive, coming in 0.7% below expectations. Its non-GAAP profit of $0.18 per share was 22.1% above analysts’ consensus estimates.
As share prices keep rising since the last few weeks, it might be a good time to consider adding Nutrien (TSX:NTR) stock to your self-directed investment portfolio.
Infrastructure construction company Primoris (NYSE:PRIM) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 6.7% year on year to $1.86 billion. Its non-GAAP profit of $1.08 per share was 8.9% above analysts’ consensus estimates.
Building products company Boise Cascade Company (NYSE:BCC) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales fell by 6.8% year on year to $1.46 billion. Its GAAP profit of $0.24 per share was significantly above analysts’ consensus estimates.
Insurance management company Erie Indemnity (NASDAQ:ERIE) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 2.9% year on year to $951 million. Its GAAP profit of $1.21 per share was 23.9% below analysts’ consensus estimates.
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 25.6% year on year to $373.1 million. Its non-GAAP profit of $1.77 per share was 2.6% above analysts’ consensus estimates.
Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue guidance of $612.5 million was less impressive, coming in 5.6% below analysts’ estimates. Its GAAP profit of $0.08 per share was 92.5% above analysts’ consensus estimates.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, but sales were flat year on year at $209.8 million. The company expects the full year’s revenue to be around $870 million, close to analysts’ estimates. Its non-GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.
Online insurance comparison site EverQuote (NASDAQ:EVER) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 32.5% year on year to $195.3 million. On the other hand, next quarter’s revenue guidance of $180 million was less impressive, coming in 7% below analysts’ estimates. Its GAAP profit of $1.54 per share was significantly above analysts’ consensus estimates.
Digital payment platform Paymentus (NYSE:PAY) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 28.1% year on year to $330.5 million. The company expects next quarter’s revenue to be around $335 million, coming in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.20 per share was 22.9% above analysts’ consensus estimates.
Specialty insurance provider Skyward Specialty Insurance (NASDAQ:SKWD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 26.7% year on year to $385.6 million. Its non-GAAP profit of $1.17 per share was 14.9% above analysts’ consensus estimates.
Theater company AMC Entertainment (NYSE:AMC) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.4% year on year to $1.29 billion. Its non-GAAP loss of $0.18 per share was 28% above analysts’ consensus estimates.
